Company news

Septerna, Inc. news in 2026

Septerna, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting

November 4, 2026

Septerna to Participate in Upcoming Investor Conferences

November 3, 2026

Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 10, 2026

Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

August 25, 2026

Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results

August 10, 2026

Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

June 8, 2026

Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results

May 11, 2026

Septerna to Present at Bank of America Securities Health Care Conference

May 5, 2026

Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

April 12, 2026

Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

March 8, 2026

Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

February 28, 2026

Septerna to Present at TD Cowen 46th Annual Health Care Conference

February 23, 2026

Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 10, 2026

Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting

February 10, 2026

Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer

January 8, 2026

Decks in 2026